Tesamorelin Powder For Anabolism And Lipolytic CAS:218949-48-5

    Introduction to Tesamorelin

    Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically engineered to mimic the biological activity of the endogenous hormone. Unlike traditional growth hormone (GH) therapies, Tesamorelin stimulates the pituitary gland to produce and release GH in a pulsatile manner, closely resembling the body's natural secretion patterns. Developed to address visceral adipose tissue (VAT) accumulation in HIV-associated lipodystrophy, it has garnered attention for its dual role in promoting lipolysis (fat breakdown) and supporting anabolism (muscle growth). This peptide's unique mechanism of action, combined with its FDA-approved status for specific conditions, positions it as a versatile therapeutic agent with applications beyond its original intent.

    2.1 Molecular Structure

    Tesamorelin (Egrifta®) is a 44-amino acid peptide with a modified structure to resist enzymatic degradation. The substitution of specific amino acids (e.g., tyrosine at position 1) enhances its stability and bioavailability, allowing for subcutaneous administration.

    2.2 Mechanism of Action

    ●GH Secretion: Binds to GHRH receptors on pituitary somatotrophs, triggering intracellular cAMP signaling and GH release.

    ●IGF-1 Mediation: GH stimulates hepatic insulin-like growth factor 1 (IGF-1), which drives anabolic processes and metabolic regulation.

    ●Visceral Fat Targeting: Reduces VAT through GH's lipolytic effects on adipocytes, particularly in abdominal depots.

    2.3 FDA Approval & Off-Label Use

    ●Primary Indication: Treatment of excess abdominal fat in HIV patients with lipodystrophy.

    ●Emerging Applications: Anti-aging, body recomposition, and metabolic syndrome management.

    3.1 Lipolytic Effects

     Tesamorelin's ability to reduce visceral fat is well-documented. In clinical trials, HIV patients experienced a 15–20% reduction in VAT over 26 weeks. This effect stems from:

    ●Hormone-Sensitive Lipase (HSL) Activation: GH increases HSL activity, breaking down triglycerides into free fatty acids.

    ●Adipocyte Apoptosis: Prolonged GH elevation may induce programmed cell death in fat cells.

    3.2 Anabolic Effects

    While not as potent as synthetic GH, Tesamorelin indirectly supports muscle growth via:

    ●IGF-1 Upregulation: Enhances protein synthesis and nitrogen retention.

    ●Anti-Catabolic Action: Reduces muscle breakdown during caloric deficits, making it valuable for cutting phases.

    3.3 Metabolic Enhancements

    ●Improves lipid profiles (reduces triglycerides, increases HDL).

    ●Enhances insulin sensitivity through VAT reduction.

    4.1 Clinical Benefits

    ●Targeted Fat Loss: Selective reduction of visceral fat without significant subcutaneous fat loss.

    ●Preservation of Lean Mass: Critical for HIV patients and athletes during weight loss.

     4.2 Performance Enhancement

    ●Non-Suppressive: Does not inhibit endogenous GH production (unlike exogenous GH).

    ●Synergy with Exercise: Amplifies fat loss and muscle definition when paired with resistance training.

    4.3 Safety Profile

    ●Minimal side effects compared to direct GH use (e.g., less edema and arthralgia).

    ●Lower risk of acromegaly due to pulsatile GH release.

    5.1 Standard Protocol

    ●HIV Lipodystrophy: 2 mg subcutaneous injection daily.

    ●Body Recomposition: 1–2 mg/day, often cycled to prevent receptor desensitization.

    5.2 Reconstitution Guidelines

    ●Use bacteriostatic water or sterile saline.

    ●Store reconstituted solution at 2–8°C for up to 21 days.

    6.1 Cycle Design

    ●Duration: 12–16 weeks, followed by a 4–8 week hiatus to restore pituitary sensitivity.

    ●Stacking: Often paired with Ipamorelin (a GHRP) for synergistic GH release.

    6.2 Half-Life

    ●Plasma Half-Life: ~26–38 minutes.

    ●Practical Implications: Requires daily dosing to maintain therapeutic GH pulses.

    Tesamorelin does not suppress the hypothalamic-pituitary axis, rendering traditional PCT unnecessary. However, users combining it with androgenic compounds may require:

    ●SERMs (e.g., Tamoxifen): To restore testosterone production.

    ●Liver Support: If stacking with oral hepatotoxic agents.

    8.1 Cognitive Benefits

    Recent studies suggest GH/IGF-1 pathways may improve neurogenesis, offering potential in neurodegenerative disease management.

    8.2 Cardiovascular Health

    VAT reduction correlates with decreased inflammation and improved endothelial function, reducing cardiovascular risk.

    8.3 Anti-Aging Potential

    By restoring GH levels to youthful patterns, Tesamorelin may combat age-related sarcopenia and frailty.

    ●Hyperglycemia: Monitor glucose levels; combine with metformin if needed.

    ●Injection-Site Reactions: Rotate injection sites and use antiseptic techniques.

Trade names	Egrifta SV, INN
CAS	218949-48-5
Molar mass	5135.86
Formula	C221H366N72O67S
Purity	Above 98%
Apprarance	White Crystalline Powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-19128233885

   

                                

 

    Tesamorelin represents a paradigm shift in managing metabolic and body composition disorders. Its ability to harness endogenous GH pulsatility offers a safer, more physiological alternative to traditional anabolic agents. While its primary use remains in HIV care, its off-label potential in sports medicine and aging underscores its versatility. Future research may expand its applications into neurology and cardiology, solidifying its role as a multifunctional therapeutic.

Hot Tags: tesamorelin powder for anabolism and lipolytic cas:218949-48-5, China tesamorelin powder for anabolism and lipolytic cas:218949-48-5 manufacturers, suppliers, factory